Arman Altincatal

976 total citations
58 papers, 656 citations indexed

About

Arman Altincatal is a scholar working on Physiology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Arman Altincatal has authored 58 papers receiving a total of 656 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Physiology, 13 papers in Immunology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Arman Altincatal's work include Asthma and respiratory diseases (22 papers), IL-33, ST2, and ILC Pathways (13 papers) and Eosinophilic Esophagitis (10 papers). Arman Altincatal is often cited by papers focused on Asthma and respiratory diseases (22 papers), IL-33, ST2, and ILC Pathways (13 papers) and Eosinophilic Esophagitis (10 papers). Arman Altincatal collaborates with scholars based in United States, France and United Kingdom. Arman Altincatal's co-authors include Tarun Bhagnani, Thomas P. Lodise, Nicole Bonine, Ariel Berger, Patrick Gillard, Shien Guo, Carl de Moor, Catherine Monk, Glenn Phillips and Maria L. Naylor and has published in prestigious journals such as Blood, PLoS ONE and Neurology.

In The Last Decade

Arman Altincatal

55 papers receiving 643 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Arman Altincatal United States	14	180	113	89	86	82	58	656
K.V.S. Hari Kumar India	18	153 0.8×	132 1.2×	61 0.7×	47 0.5×	71 0.9×	121	1.1k
Chih‐Hung Ku Taiwan	18	33 0.2×	73 0.6×	40 0.4×	25 0.3×	140 1.7×	57	847
Wenjing Wei United States	15	17 0.1×	34 0.3×	16 0.2×	120 1.4×	62 0.8×	39	658
Amira Al‐Uzri United States	15	33 0.2×	84 0.7×	95 1.1×	17 0.2×	79 1.0×	53	998
George Panayiotakopoulos Greece	13	31 0.2×	40 0.4×	67 0.8×	31 0.4×	32 0.4×	39	633
G Giuffrida Italy	21	87 0.5×	35 0.3×	112 1.3×	49 0.6×	70 0.9×	65	1.2k
Ronald B. Brown Canada	13	70 0.4×	70 0.6×	44 0.5×	31 0.4×	40 0.5×	56	638
Meng-Chih Lin Taiwan	15	15 0.1×	142 1.3×	48 0.5×	50 0.6×	255 3.1×	24	742
WK Lam Hong Kong	16	26 0.1×	431 3.8×	30 0.3×	13 0.2×	575 7.0×	50	1.2k

Countries citing papers authored by Arman Altincatal

Since Specialization

Citations

This map shows the geographic impact of Arman Altincatal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arman Altincatal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arman Altincatal more than expected).

Fields of papers citing papers by Arman Altincatal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arman Altincatal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arman Altincatal. The network helps show where Arman Altincatal may publish in the future.

Co-authorship network of co-authors of Arman Altincatal

This figure shows the co-authorship network connecting the top 25 collaborators of Arman Altincatal. A scholar is included among the top collaborators of Arman Altincatal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arman Altincatal. Arman Altincatal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Phipatanakul, Wanda, Christian Vogelberg, Leonard B. Bacharier, et al.. (2024). Dupilumab 200 mg was efficacious in children (6–11 years) with moderate‐to‐severe asthma for up to 2 years: EXCURSION open‐label extension study. Pediatric Pulmonology. 59(11). 2976–2983. 2 indexed citations

Busse, William W., Ian Pavord, Michael E. Wechsler, et al.. (2024). Stability of Fractional Exhaled Nitric Oxide and Its Relationship With Exacerbation in Patients Aged 6 Years or Older With Uncontrolled, Moderate-to-Severe Asthma. CHEST Journal. 167(6). 1541–1546.

Pavord, Ian, Klaus F. Rabe, Elliot Israel, et al.. (2024). Dupilumab Induces Long-Term On-Treatment Clinical Remission in Patients With Type 2 Asthma. The Journal of Allergy and Clinical Immunology In Practice. 13(1). 132–142. 15 indexed citations

Wechsler, Michael E., Linda Rogers, Giorgio Walter Canonica, et al.. (2024). Long-term dupilumab efficacy in type 2 asthma regardless of baseline characteristics. ERJ Open Research. 10(6). 188–2024.

Máspero, Jorge, Martti Antila, A. Deschildre, et al.. (2024). Dupilumab Efficacy in Children With Type 2 Asthma Receiving High- to Medium-Dose Inhaled Corticosteroids (VOYAGE). The Journal of Allergy and Clinical Immunology In Practice. 12(12). 3303–3312. 3 indexed citations

Rabe, Klaus F., Ian Pavord, William W. Busse, et al.. (2023). Dupilumab improves long‐term outcomes in patients with uncontrolled, moderate‐to‐severe GINA‐based type 2 asthma, irrespective of allergic status. Allergy. 78(8). 2148–2156. 6 indexed citations

Niino, Masaaki, Yusei Miyazaki, Arman Altincatal, et al.. (2023). Processing speed test: Results from a Japanese normative sample of healthy participants compared with a US normative sample. Clinical Neurology and Neurosurgery. 230. 107790–107790. 5 indexed citations

Pavord, Ian, Arnaud Bourdin, Alberto Papi, et al.. (2023). Dupilumab sustains efficacy in patients with moderate‐to‐severe type 2 asthma regardless of inhaled corticosteroids dose. Allergy. 78(11). 2921–2932. 6 indexed citations

Corren, Jonathan, David J. Jackson, Thomas B. Casale, et al.. (2023). Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization. Journal of Asthma and Allergy. Volume 16. 249–260. 4 indexed citations

10.

Corren, Jonathan, Nicola A. Hanania, William W. Busse, et al.. (2023). Efficacy of dupilumab in patients with uncontrolled, moderate‐to‐severe asthma with fungal sensitization. Clinical & Experimental Allergy. 53(10). 1020–1030. 3 indexed citations

11.

Hanania, Nicola A., Mario Castro, Eric D. Bateman, et al.. (2022). Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction. Annals of Allergy Asthma & Immunology. 130(2). 206–214.e2. 8 indexed citations

12.

Hersh, Carrie M., Arman Altincatal, Carl de Moor, et al.. (2022). Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics. Multiple Sclerosis Journal - Experimental Translational and Clinical. 8(1). 3080433052–3080433052. 7 indexed citations

13.

Reder, Anthony T., Diego Centonze, Maria L. Naylor, et al.. (2021). COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 35(3). 317–330. 85 indexed citations

14.

Altincatal, Arman, et al.. (2021). Linking Ambulance Trip and Emergency Department Surveillance Data on Opioid-Related Overdose, Massachusetts, 2017. Public Health Reports. 136(1_suppl). 47S–53S. 4 indexed citations

15.

Galetta, Steven, Laura J. Balcer, Arman Altincatal, et al.. (2021). Retinal Structure and Function as a Predictor of Long-Term Visual Outcomes: A Post Hoc Analysis of RENEW and RENEWED (1945). Neurology. 96(15_supplement). 1 indexed citations

16.

Newsome, Scott D., Thomas F. Scott, Douglas L. Arnold, Arman Altincatal, & Maria L. Naylor. (2021). Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN. Multiple Sclerosis and Related Disorders. 57. 103367–103367. 2 indexed citations

17.

Deniz, Baris, Shuo Yang, Arman Altincatal, et al.. (2019). Treatment sequences for advanced renal cell carcinoma: A health economic assessment. PLoS ONE. 14(8). e0215761–e0215761. 15 indexed citations

18.

Ashaye, Ajibade, et al.. (2015). Estimating Eortc-8d Health State Utility Values From Eortc Qlq-C30 Scores In Relapsed Multiple Myeloma. Value in Health. 18(7). A468–A468. 1 indexed citations

19.

Lawson, Richard, et al.. (2014). How Does Non-Malignant Opioid Induced Constipation (Oic) Impact Health State Utility?. Value in Health. 17(7). A369–A369. 2 indexed citations

20.

Werner, Elizabeth, Yihong Zhao, Lynn M. Evans, et al.. (2012). Higher maternal prenatal cortisol and younger age predict greater infant reactivity to novelty at 4 months: An observation‐based study. Developmental Psychobiology. 55(7). 707–718. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact